



On the Radar

Issue 333

7 August 2017

On the Radar is a summary of some of the recent publications in the areas of safety and quality in health care. Inclusion in this document is not an endorsement or recommendation of any publication or provider. Access to particular documents may depend on whether they are Open Access or not, and/or your individual or institutional access to subscription sites/services. Material that may require subscription is included as it is considered relevant.

On the Radar is available online, via email or as a PDF or Word document from <https://www.safetyandquality.gov.au/publications-resources/on-the-radar/>

If you would like to receive *On the Radar* via email, you can subscribe on our website <https://www.safetyandquality.gov.au/> or by emailing us at mail@safetyandquality.gov.au. You can also send feedback and comments to mail@safetyandquality.gov.au.

For information about the Commission and its programs and publications, please visit <https://www.safetyandquality.gov.au>
You can also follow us on Twitter @ACSQHC.

On the Radar

Editor: Dr Niall Johnson niall.johnson@safetyandquality.gov.au

Contributors: Niall Johnson

AURA 2017: second Australian report on antimicrobial use and resistance in human health

Australian Commission on Safety and Quality in Health Care (ACSQHC)

Sydney: ACSQHC; 2017. p.238.

<https://www.safetyandquality.gov.au/antimicrobial-use-and-resistance-in-australia/2017-report/>

As part of the Australian Government's First National Antimicrobial Resistance Strategy 2015–2019 to prevent and contain antimicrobial resistance, the Australian Commission on Safety and Quality in Health Care established the national surveillance system for Antimicrobial Use and Resistance in Australia (AURA).

The Commission has released *AURA 2017: Second Australian report on antimicrobial use and resistance in human health*. This report increases the comprehensiveness of the picture of antimicrobial use, resistance and the appropriateness of prescribing in Australia across all healthcare settings.

Key findings include:

- In 2015, 44.7% of the Australian population (10.7 million people) had at least one antimicrobial dispensed in the community
- More than 30 million antimicrobial prescriptions were dispensed through the PBS/RPBS in 2015
- Antimicrobial resistances require focused infection control effort in hospitals to reduce their spread

- On any given day in an Australian hospital in 2015, 40.5% of patients were being administered an antimicrobial; of these, 23.3% of antimicrobial prescriptions were not compliant with guidelines, and 21.9% were considered inappropriate
- Antibiotics used in hospitals for surgery (surgical prophylaxis) are often not required and are given for too long. In 2015, 40.5% of surgical prophylaxis in hospitals was inappropriate, mainly because of incorrect duration (29.9%); incorrect dose or frequency (27.6%); or the procedure did not require antibiotics (22.0%)
- Colds and flu are viral respiratory infections that cannot be treated with antibiotics; the use of antibiotics for these conditions exposes patients to the risk of unwanted side effects and drives antimicrobial resistance
- There are concerning levels of use of antimicrobials in aged care homes for residents who do not have documented signs and symptoms of infection, and there is poor documentation of the indication of antibiotics and a review or stop date.

The report contains a range of findings on antimicrobial resistance and highlights a number of areas for action to help reduce antimicrobial resistance, including reducing unnecessary prescribing in the community, actions to control carbapenemase-producing Enterobacteriaceae, monitoring resistant gonococcal infections, minimising the spread of vancomycin-resistant enterococci, improving the appropriateness of antimicrobial use for surgical prophylaxis.

Antimicrobial use in Australia in 2015

30,452,371 prescriptions were dispensed in the community.

Almost half or 44.7% of people in Australia had a least 1 antimicrobial dispensed.

**In aged care homes
around 20%**

of antimicrobial prescriptions were for people who had no signs or symptoms of infection.

**In the community
For 60% of people**

in the community who presented to a general practitioner with colds and upper respiratory infections, no justification was recorded for why an antimicrobial was prescribed.

Antimicrobials are not generally recommended for colds and upper respiratory tract infections



AUSTRALIAN COMMISSION
ON SAFETY AND QUALITY IN HEALTH CARE



www.safetyandquality.gov.au/antimicrobial-use-and-resistance-in-australia

Reports

Economic evaluation of investigator-initiated clinical trials conducted by networks


Australian Clinical Trials Alliance

Sydney: ACSQHC; 2017. p.74.

<p>URL</p> <p>Notes</p>	<p>https://www.safetyandquality.gov.au/our-work/clinical-trials/</p> <p>The Australian Commission on Safety and Quality in Health Care sought to understand the full potential of clinical trials to influence health outcomes as well as their economic impact. The Commission engaged the Australian Clinical Trials Alliance, in partnership with Quantum Health Outcomes, to evaluate the overall health and economic impact of investigator-initiated clinical trials conducted by networks.</p> <p>The study assessed investigator-initiated clinical trials conducted by select clinical trials networks in Australia, including the Australasian Stroke Trials Network (ASTN), the Interdisciplinary Maternal Perinatal Australasian Collaborative Trials (IMPACT) Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG).</p> <p>Focussing on 25 high-impact clinical trials evaluated across the three networks, the report found that if the results of these trials were implemented in 65% of the eligible Australian patient populations for one year:</p> <ul style="list-style-type: none"> • The gross benefit would be approximately \$2 billion measured through better health outcomes and reduced health service costs • Reductions in health service costs would account for 30% (\$580 million) of the gross benefit, and this alone would exceed the total costs for the three networks and all of their research activity from 2004 to 2014. • The overall consolidated benefit-to-cost ratio for the networks is 5.8:1, or a return of \$5.80 for every \$1 invested • The results of the 25 trials only needed to be implemented in 11% of the eligible patient populations for benefits to exceed costs • For every \$1 awarded in National Health and Medical Research Council (NHMRC) grants to the 25 trials, a return of \$51.10 was achieved
-------------------------	--

Journal articles

Drug shortage leading to serendipitous adoption of high-value care practice
 Gupta A, Rahman A, Alvarez KS, Gard JW, Johnson DH, Agrawal D
 BMJ Quality & Safety. 2017.

DOI	http://dx.doi.org/10.1136/bmjqs-2017-007015																																																												
Notes	<p>This piece describes the initial impact and lasting effect of a shortage of a particular medication in a hospital. In this instance a large (870-bed) teaching hospital was informed of a critical shortage of an intravenous proton pump inhibitor (PPI). As the authors point out, “PPIs are one of the most overused medications, and the intravenous route is often used when oral administration would suffice, significantly increasing medication and administration costs... Intravenous PPIs are recommended only in patients with active upper gastrointestinal bleeding prior to endoscopy, and sometimes after endoscopic treatment of an ulcer.” A retrospective review of the 12 months prior to the shortage found only 16% of orders were for active upper gastrointestinal bleeding.</p> <p>When the shortage was announced, a number of interventions were implemented, including:</p> <ol style="list-style-type: none"> (1) on single order entry, a clinical decision support message was created in the electronic medical record advising limiting the use of intravenous PPI to patients with active upper gastrointestinal bleeding (2) all remaining intravenous PPI orders required pharmacy approval prior to execution (3) order panels including continuous intravenous PPI had automatic stop orders after 24 hours panelled with a step down to oral PPI to complete therapy. <p>These were then retained even after the shortage was resolved. The authors report that “Over the next 2 years, the decrease in use of intravenous PPI has been sustained, an approximate 75% reduction from baseline use. The estimated cumulative cost saving of this intervention has been \$200 000. More importantly, we noticed a change in the ordering pattern of providers, and pharmacists had to perform minimal order entry outside of the prebuilt order sets and panels as time passed. There were no reported adverse clinical outcomes.”</p> <p>They also note that “rapid adoption of high-value change is possible”. It also reinforces the adage about never letting a crisis go to waste. It can be an opportunity to review practice and behaviour.</p>  <table border="1"> <caption>Estimated data for Total cost of intravenous PPI</caption> <thead> <tr> <th>Month-year</th> <th>Total cost of intravenous PPI (\$)</th> </tr> </thead> <tbody> <tr><td>Oct-14</td><td>14,000</td></tr> <tr><td>Nov-14</td><td>12,000</td></tr> <tr><td>Dec-14</td><td>11,000</td></tr> <tr><td>Jan-15</td><td>10,000</td></tr> <tr><td>Feb-15</td><td>9,000</td></tr> <tr><td>Mar-15</td><td>9,000</td></tr> <tr><td>Apr-15</td><td>10,000</td></tr> <tr><td>May-15</td><td>52,000</td></tr> <tr><td>Jun-15</td><td>4,000</td></tr> <tr><td>Jul-15</td><td>3,000</td></tr> <tr><td>Aug-15</td><td>2,000</td></tr> <tr><td>Sep-15</td><td>1,000</td></tr> <tr><td>Oct-15</td><td>1,000</td></tr> <tr><td>Nov-15</td><td>2,000</td></tr> <tr><td>Dec-15</td><td>1,000</td></tr> <tr><td>Jan-16</td><td>1,000</td></tr> <tr><td>Feb-16</td><td>1,000</td></tr> <tr><td>Mar-16</td><td>3,000</td></tr> <tr><td>Apr-16</td><td>2,000</td></tr> <tr><td>May-16</td><td>2,000</td></tr> <tr><td>Jun-16</td><td>2,000</td></tr> <tr><td>Jul-16</td><td>4,000</td></tr> <tr><td>Aug-16</td><td>2,000</td></tr> <tr><td>Sep-16</td><td>2,000</td></tr> <tr><td>Oct-16</td><td>3,000</td></tr> <tr><td>Nov-16</td><td>4,000</td></tr> <tr><td>Dec-16</td><td>2,000</td></tr> <tr><td>Jan-17</td><td>2,000</td></tr> <tr><td>Feb-17</td><td>2,000</td></tr> </tbody> </table>	Month-year	Total cost of intravenous PPI (\$)	Oct-14	14,000	Nov-14	12,000	Dec-14	11,000	Jan-15	10,000	Feb-15	9,000	Mar-15	9,000	Apr-15	10,000	May-15	52,000	Jun-15	4,000	Jul-15	3,000	Aug-15	2,000	Sep-15	1,000	Oct-15	1,000	Nov-15	2,000	Dec-15	1,000	Jan-16	1,000	Feb-16	1,000	Mar-16	3,000	Apr-16	2,000	May-16	2,000	Jun-16	2,000	Jul-16	4,000	Aug-16	2,000	Sep-16	2,000	Oct-16	3,000	Nov-16	4,000	Dec-16	2,000	Jan-17	2,000	Feb-17	2,000
Month-year	Total cost of intravenous PPI (\$)																																																												
Oct-14	14,000																																																												
Nov-14	12,000																																																												
Dec-14	11,000																																																												
Jan-15	10,000																																																												
Feb-15	9,000																																																												
Mar-15	9,000																																																												
Apr-15	10,000																																																												
May-15	52,000																																																												
Jun-15	4,000																																																												
Jul-15	3,000																																																												
Aug-15	2,000																																																												
Sep-15	1,000																																																												
Oct-15	1,000																																																												
Nov-15	2,000																																																												
Dec-15	1,000																																																												
Jan-16	1,000																																																												
Feb-16	1,000																																																												
Mar-16	3,000																																																												
Apr-16	2,000																																																												
May-16	2,000																																																												
Jun-16	2,000																																																												
Jul-16	4,000																																																												
Aug-16	2,000																																																												
Sep-16	2,000																																																												
Oct-16	3,000																																																												
Nov-16	4,000																																																												
Dec-16	2,000																																																												
Jan-17	2,000																																																												
Feb-17	2,000																																																												

For information the Commission’s work on medication safety, see <https://www.safetyandquality.gov.au/our-work/medication-safety/>

The third global patient safety challenge: tackling medication-related harm
 Sheikh A, Dhingra-Kumar N, Kelley E, Kieny MP, Donaldson LJ
 Bulletin of the World Health Organization. 2017;95:546-a.

DOI	http://dx.doi.org/10.2471/BLT.17.198002
Notes	<p>Editorial in the Bulletin of the World Health Organization describing the WHO’s recent announcement of its third global patient safety challenge, Medication without harm. This challenge aims to reduce the global burden of iatrogenic medication-related harm by 50% within five years. A number of priority areas that most affect patients have been identified. These include high-risk situations, polypharmacy and transitions of care.</p> <p>The WHO’s challenge invites health ministers to initiate national plans addressing four domains of medication safety:</p> <ul style="list-style-type: none"> • engaging patients and the public • medication as products • education, training and monitoring of health-care professionals • systems and practices of medication management. <p>The WHO’s role in this challenge would be to drive forward a range of global actions on medication safety. The WHO’s webpage for this challenge is at http://www.who.int/patientsafety/medication-safety/en/</p>

A trip to healthcare
 Matz DE
 Patient Experience Journal. 2017;4(2):9-12.

The paradigm of patient must evolve: Why a false sense of limited capacity can subvert all attempts at patient involvement
 deBronkart D
 Patient Experience Journal. 2017;4(2):4-8.

URL	Matz http://pxjournal.org/journal/vol4/iss2/3/ deBronkart http://pxjournal.org/journal/vol4/iss2/2/
Notes	<p>A pair of items in the latest issue of the <i>Patient Experience Journal</i> that use narratives of complex or critical patient journeys (again, make use of the crises) to draw out important themes or learnings.</p> <p>David Matz’s experience (two colonoscopies and three surgeries) prompted him to recommend:</p> <ul style="list-style-type: none"> • Every doctor in a diagnostic-decision-making interview should use the sentence “You have some choices here.” The doctor will have preferences, of course, but the patient needs to hear that there is more than one way to take the next step. • For diagnostic-decision-making moments, all doctors (and hospitals) should provide patients with support personnel to help the patients use decision-aids, prepare for discussions with doctors, and make the decisions. <p>David deBronkart’s experience (Stage IV renal cell carcinoma) makes him reflect on the definition and role(s) of the patient with him advocating for much more engagement, activation and empowerment of the patient. He reminds us of the World Bank’s definition : “Empowerment is increasing [someone’s] capacity to make choices, and to convert those choices into effective actions and outcomes.”</p>

For information the Commission's work on patient and consumer centred care, see <https://www.safetyandquality.gov.au/our-work/patient-and-consumer-centred-care/>

Australian Health Review

Volume 41 Number 4 2017

URL	http://www.publish.csiro.au/ah/issue/8492
Notes	<p>A new issue of <i>Australian Health Review</i> has been published. Articles in this issues of <i>Australian Health Review</i> include:</p> <ul style="list-style-type: none"> • Are organisational factors affecting the emotional withdrawal of community nurses? (Leila Karimi, Sandra G. Leggat, Cindy Cheng, Lisa Donohue, Timothy Bartram and Jodi Oakman) • Experience of clinical supervisors of international medical graduates in an Australian district hospital (David Henderson, Pam D McGrath and Mary Anne Patton) • Survey of parent and carer experiences and expectations of paediatric rheumatology care in New South Wales (Andrea Coda, Julie Jones, Debra Grech and Davinder Singh Grewal) • Identification of major factors in Australian primary care pharmacists' practice environment that have a bearing on the implementation of professional models of practice (John K Jackson, Safeera Y Hussainy and Carl M J Kirkpatrick) • Beyond clinical priority: what matters when making operational decisions about emergency surgical queues? (Anneke Fitzgerald and Yong Wu) • Growth of linked hospital data use in Australia: a systematic review (Michelle Tew, Kim M Dalziel, Dennis J Petrie and Philip M Clarke) • Parental preferences for paediatric specialty follow-up care (Marina Kunin, Erin Turbitt, Sarah A Gafforini, Lena A Sanci, Neil A Spike and Gary L Freed) • Identifying areas of need relative to liver disease: geographic clustering within a health service district (Nathan El-Atem, K M Irvine, P C Valery, K Wojcik, L Horsfall, T Johnson, M Janda, S M McPhail and E E Powell) • Patients' experiences in Australian hospitals: a systematic review of evidence (Reema Harrison, Merrilyn Walton, Elizabeth Manias, Steven Mears and Jennifer Plumb) • Informed consent in a vulnerable population group: supporting individuals aging with intellectual disability to participate in developing their own health and support programs (Stuart Wark, Catherine MacPhail, Kathy McKay and Arne Müller) • Improving the accuracy of admitted subacute clinical costing: an action research approach (Sharon Hakkennes, Ross Arblaster and Kim Lim) • What systems participants know about access and service entry and why managers should listen (Rohena Duncombe) • Social participation as an indicator of successful aging: an overview of concepts and their associations with health (Heather Douglas, Andrew Georgiou and Johanna Westbrook) • Practical applications of rapid review methods in the development of Australian health policy (Robyn Lambert, Thomas D Vreugdenburg, Nicholas Marlow, N Ann Scott, Lynda McGahan and David Tivey) • Caries and periodontal disease in Indigenous adults in Australia: a case of limited and non-contemporary data (Andrea M de Silva, Jacqueline M Martin-Kerry, Katherine McKee and Deborah Cole)

URL	http://pxjournal.org/journal/vol4/iss2/
Notes	<p>A special issue of the <i>Patient Experience Journal</i> (PXJ) has been published. This special issue focused on Patient Involvement. The editors state that “By including the voices of patients, practitioners and researchers in the publication, this special issue is focused on how involving patients and families as partners drives better healthcare outcomes overall.” Articles in this special issue of the <i>Patient Experience Journal</i> include:</p> <ul style="list-style-type: none"> • Pushing the boundaries of patient experience (Jason A Wolf) • The paradigm of patient must evolve: Why a false sense of limited capacity can subvert all attempts at patient involvement (Dave deBronkart) • A trip to healthcare (david e matz) • Lack of patient involvement in care decisions and not receiving written discharge instructions are associated with unplanned readmissions up to one year (Kyle A Kemp, Hude Quan, and Maria J Santana) • Understanding the role of patient and public involvement in renal dietetic research (Andrew Morris, Deborah Biggerstaff, Nithya Krishnan, and Deborah Lycett) • Integrating person directed care into the client experience (Tammy L Marshall, Joann P Reinhardt, Orah Burack, and Audrey S Weiner) • Increasing sustainability in co-design projects: A qualitative evaluation of a co-design programme in New Zealand (Lynne Margaret Maher, Brooke Hayward, Patricia Hayward, and Chris Walsh) • Experience-based co-design: A method for patient and family engagement in system-level quality improvement (Bianca Fucile, Erica Bridge, Charlene Duliban, and Madelyn P. Law)

International Journal for Quality in Health Care online first articles

URL	https://academic.oup.com/intqhc/advance-access?papetoc
Notes	<p><i>International Journal for Quality in Health Care</i> has published a number of ‘online first’ articles, including:</p> <ul style="list-style-type: none"> • Reporting of medication administration errors by nurses in South Korean hospitals (Eunjoo Lee) • Evaluating the impact of accreditation on Brazilian healthcare organizations: A quantitative study (Ana Maria Saut; Fernando Tobal Berssaneti; Maria Carolina Moreno) • A comparison of in-hospital acute myocardial infarction management between Portugal and the United States: 2000–2010 (Mariana F. Lobo; Vanessa Azzone; Luís Filipe Azevedo; Bruno Melica; Alberto Freitas; Leonor Bacelar-Nicolau; Francisco N. Rocha-Gonçalves; Cláudia Nisa; Armando Teixeira-Pinto; José Pereira-Miguel; Frederic S. Resnic; Altamiro Costa-Pereira; Sharon-Lise Normand) • Are children presenting with non-IMCI complaints at greater risk for suboptimal screening? An analysis of outpatient visits in Afghanistan (Maya Venkataramani; Anbrasi Edward; Paul Ickx; Motawali Younusi; Syed Ali Shah Alawi; David H Peters)

URL	https://qualitysafety.bmj.com/content/early/recent
Notes	<p>BMJ <i>Quality and Safety</i> has published a number of ‘online first’ articles, including:</p> <ul style="list-style-type: none"> • How to attribute causality in quality improvement: lessons from epidemiology (Alan J Poots, Julie E Reed, T Woodcock, D Bell, D Goldmann) • Factors influencing the reporting of adverse medical device events: qualitative interviews with physicians about higher risk implantable devices (Anna R Gagliardi, Ariel Ducey, Pascale Lehoux, Thomas Turgeon, Sue Ross, Patricia Trvovich, Anthony Easty, Chaim Bell, David Urbach) • The use of patient feedback by hospital boards of directors: a qualitative study of two NHS hospitals in England (Robert Lee, Juan I Baeza, N J Fulop) • Drug shortage leading to serendipitous adoption of high-value care practice (Arjun Gupta, A Rahman, K S Alvarez, J W Gard, D H Johnson, D Agrawal) • Does early return to theatre add value to rates of revision at 3 years in assessing surgeon performance for elective hip and knee arthroplasty? National observational study (Alex Bottle, H E Chase, P P Aylin, M Loeffler) • Outpatient CPOE orders discontinued due to ‘erroneous entry’: prospective survey of prescribers’ explanations for errors (Thu-Trang T Hickman, Arbor Jessica Lauren Quist, Alejandra Salazar, Mary G Amato, Adam Wright, Lynn A Volk, David W Bates, Gordon Schiff) • Consistency of pressure injury documentation across interfacility transfers (Lee Squitieri, David A Ganz, Carol M Mangione, Jack Needleman, Patrick S Romano, Debra Saliba, Clifford Y Ko, Daniel A Waxman) • Enhancing problem list documentation in electronic health records using two methods: the example of prior splenectomy (Dustin McEvoy, Tejal K. Gandhi, Alexander Turchin, Adam Wright)

Online resources

[UK] National Institute for Health Research

<https://discover.dc.nihr.ac.uk/portal/search/signals>

The UK’s National Institute for Health Research (NIHR) Dissemination Centre has released the latest ‘Signals’ research summaries. This latest release includes:

- **Type 2 diabetes** is becoming more common in children
- Treatments for reducing **menopausal hot flushes** are ranked for effectiveness
- Physical activity in the community improves **mobility** for **cancer survivors**
- Regional anaesthesia could improve **fistula** function for **kidney dialysis**
- Tenofovir reduces mother-to-child **hepatitis B transmission**
- Online education, pain coaching and advice by video conference can reduce **knee pain**
- Intensive **speech therapy** helps **stroke survivors** with persistent communication difficulties
- Screen reminders for GPs did not improve **anticoagulant** prescribing in **atrial fibrillation**
- Continuous **insulin pumps** may help manage poorly controlled **type 2 diabetes**
- **Public health interventions** may offer a return on investment of £14 for each £1 spent

Disclaimer

On the Radar is an information resource of the Australian Commission on Safety and Quality in Health Care. The Commission is not responsible for the content of, nor does it endorse, any articles or sites listed. The Commission accepts no liability for the information or advice provided by these external links. Links are provided on the basis that users make their own decisions about the accuracy, currency and reliability of the information contained therein. Any opinions expressed are not necessarily those of the Australian Commission on Safety and Quality in Health Care.